UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K
Rhea-AI Filing Summary
UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock. The filing lists the sale date as 05/08/2026 with aggregate proceeds of $300,048.00. The underlying shares were issued on 01/27/2023 following a stock option exercise.
Positive
- None.
Negative
- None.
Insights
Form 144 sale notice for 10,000 shares with $300,048 proceeds.
The filing lists a 10,000-share sale reported on 05/08/2026, showing aggregate proceeds of $300,048.00. The shares trace to a stock option exercise dated 01/27/2023.
Regulatory treatment appears routine: the notice documents a broker-assisted resale on NASDAQ through RBC Capital Markets. Timing, selling holder identity, and whether sales were part of a larger plan are not detailed in the excerpt.
Key Figures
Key Terms
Form 144 regulatory
Stock option exercise financial
Aggregate proceeds financial
FAQ
What does UroGen's (URGN) Form 144 report show?
Who acted as broker for the sale reported in the Form 144?
Does the Form 144 specify who the selling holder is?
AI-generated analysis. How Rhea-AI works. Not financial advice.